ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

FDA Updates Safety Information for 5-Alpha Reductase Inhibitors

June 17, 2011

FEBT, For Pain Control, Shows Positive Results In Phase III

May 26, 2006

Program Monitors Resistance In Antimicrobial And Antifungal Therapies for Cancer Patients

November 29, 2002

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

NIH Acknowledges Role Of Pasteur Virus In AIDS Test, Gives France More Royalties

July 15, 1994

Eight Years Later:In A Change of Heart, LCA Endorses NLST

April 18, 2014